Original Research J Clin Psychiatry March 2021

The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States

JCP 2021;82(2):10.4088/JCP.20m13699

Full Article Read the complete peer-reviewed article in J Clin Psychiatry. JCP 2021;82(2):10.4088/JCP.20m13699 Clinical Summary Many patients with major depressive disorder do not respond after multiple antidepressant trials, and the downstream burden extends well beyond clinic visits to lost work and unemployment. This analysis quantifies how much treatment-resistant depression accounts for the national burden of medication-treated MDD in the United States, showing that a minority of patients drive a disproportionate share of costs. FAQ How common was treatment-resistant depression among US adults receiving medication for major depressive disorder in this study? 10 questions
Key Takeaways The model estimated 8.95 million US adults with medication-treated MDD, including 2.76 million with TRD and 6.19 million with non-TRD MDD, underscoring how often treatment resistance emerges within routine antidepressant care. 6 takeaways Clinical Guide How can clinicians or health systems operationally identify treatment-resistant depression among adults receiving medication treatment for major depressive disorder? 5 steps Clinical Guide How can clinicians operationally identify treatment-resistant depression in adults receiving medication treatment for major depressive disorder? 5 steps